# A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

> **NCT00993018** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 77 (actual)

## Conditions studied

- Diabetic Neuropathy

## Interventions

- **DRUG:** JNJ-42160443 (1 mg)
- **DRUG:** JNJ-42160443 (3 mg)
- **DRUG:** JNJ-42160443 (10 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00993018
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Logistic reasons associated with the FDA-imposed clinical hold.
- **Last updated:** 2016-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993018, "A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00993018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*